RU2003120442A - MACROHETEROCYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS - Google Patents
MACROHETEROCYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORSInfo
- Publication number
- RU2003120442A RU2003120442A RU2003120442/04A RU2003120442A RU2003120442A RU 2003120442 A RU2003120442 A RU 2003120442A RU 2003120442/04 A RU2003120442/04 A RU 2003120442/04A RU 2003120442 A RU2003120442 A RU 2003120442A RU 2003120442 A RU2003120442 A RU 2003120442A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- independently selected
- amino
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 30
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 522
- 125000001424 substituent group Chemical group 0.000 claims 154
- 125000003545 alkoxy group Chemical group 0.000 claims 141
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 139
- 229910052739 hydrogen Inorganic materials 0.000 claims 132
- 239000001257 hydrogen Substances 0.000 claims 132
- 229910052736 halogen Inorganic materials 0.000 claims 128
- 150000002367 halogens Chemical class 0.000 claims 101
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 94
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 89
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 85
- 125000000623 heterocyclic group Chemical group 0.000 claims 72
- 229910052799 carbon Inorganic materials 0.000 claims 58
- 125000005843 halogen group Chemical group 0.000 claims 44
- 125000004043 oxo group Chemical group O=* 0.000 claims 43
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 37
- 125000000304 alkynyl group Chemical group 0.000 claims 35
- 125000003342 alkenyl group Chemical group 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 125000005418 aryl aryl group Chemical group 0.000 claims 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 201000010099 disease Diseases 0.000 claims 22
- 125000003277 amino group Chemical compound 0.000 claims 21
- -1 hydroxy, hydroxy Chemical group 0.000 claims 19
- 102000001253 Protein Kinases Human genes 0.000 claims 18
- 108091000081 Phosphotransferases Proteins 0.000 claims 14
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 13
- 125000005647 linker group Chemical group 0.000 claims 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 9
- 230000001404 mediated Effects 0.000 claims 9
- 206010012601 Diabetes mellitus Diseases 0.000 claims 8
- 150000001721 carbon Chemical group 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010021425 Immune system disease Diseases 0.000 claims 6
- 206010061255 Ischaemia Diseases 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical compound 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000000449 nitro group Chemical compound [O-][N+](*)=O 0.000 claims 5
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 4
- 102000001267 GSK3 Human genes 0.000 claims 4
- 102100007245 GSK3B Human genes 0.000 claims 4
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 4
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims 4
- 102100007893 PRKCA Human genes 0.000 claims 4
- 102100019685 PRKCG Human genes 0.000 claims 4
- 108090000315 Protein Kinase C Proteins 0.000 claims 4
- 102000003923 Protein Kinase C Human genes 0.000 claims 4
- 108010050276 Protein Kinase C-alpha Proteins 0.000 claims 4
- 108060006633 Protein Kinases Proteins 0.000 claims 4
- 125000004414 alkyl thio group Chemical compound 0.000 claims 4
- 201000004384 alopecia Diseases 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 125000004093 cyano group Chemical compound *C#N 0.000 claims 4
- 230000003676 hair loss Effects 0.000 claims 4
- 200000000018 inflammatory disease Diseases 0.000 claims 4
- 108010062154 protein kinase C gamma Proteins 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 150000003839 salts Chemical compound 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- HFBYLYCMISIEMM-FFHNEAJVSA-N (4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid Chemical compound OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC HFBYLYCMISIEMM-FFHNEAJVSA-N 0.000 claims 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1H-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims 2
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 206010004939 Bipolar I disease Diseases 0.000 claims 2
- 206010004938 Bipolar disease Diseases 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010007554 Cardiac failure Diseases 0.000 claims 2
- 208000005846 Cardiomyopathy Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010057668 Cognitive disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010019280 Heart failure Diseases 0.000 claims 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010022114 Injury Diseases 0.000 claims 2
- 208000001083 Kidney Disease Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010029149 Nephropathy Diseases 0.000 claims 2
- 206010029151 Nephropathy Diseases 0.000 claims 2
- 208000009025 Nervous System Disease Diseases 0.000 claims 2
- 208000004296 Neuralgia Diseases 0.000 claims 2
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000005107 Premature Birth Diseases 0.000 claims 2
- 206010036590 Premature baby Diseases 0.000 claims 2
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims 2
- 206010038932 Retinopathy Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 230000001154 acute Effects 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 201000008031 cardiomyopathy Diseases 0.000 claims 2
- 230000000271 cardiovascular Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 230000000051 modifying Effects 0.000 claims 2
- 201000008895 mood disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000002829 nitrogen Chemical group 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000035699 permeability Effects 0.000 claims 2
- 230000002062 proliferating Effects 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 200000000008 restenosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000010802 sludge Substances 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1H-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 claims 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010061256 Ischaemic stroke Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000000771 oncological Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000001052 transient Effects 0.000 claims 1
- 0 C*(C=C1)C=Cc2c1c(C(C(N1)=O)=C3C1=O)c[n]2**C*N1C2=CC=C(C)CC=C2C3=C1 Chemical compound C*(C=C1)C=Cc2c1c(C(C(N1)=O)=C3C1=O)c[n]2**C*N1C2=CC=C(C)CC=C2C3=C1 0.000 description 3
Claims (56)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25416100P | 2000-12-08 | 2000-12-08 | |
US60/254,161 | 2000-12-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2003120442A true RU2003120442A (en) | 2004-12-27 |
RU2275373C2 RU2275373C2 (en) | 2006-04-27 |
Family
ID=22963161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2003120442/04A RU2275373C2 (en) | 2000-12-08 | 2001-12-06 | Macroheterocyclic compounds |
Country Status (12)
Country | Link |
---|---|
US (1) | US6828327B2 (en) |
EP (1) | EP1345946B1 (en) |
JP (1) | JP2004526676A (en) |
AT (1) | ATE301661T1 (en) |
AU (2) | AU2737102A (en) |
CA (1) | CA2431187A1 (en) |
DE (1) | DE60112611T2 (en) |
ES (1) | ES2245994T3 (en) |
HK (1) | HK1055956A1 (en) |
MX (1) | MXPA03005139A (en) |
RU (1) | RU2275373C2 (en) |
WO (1) | WO2002046197A1 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2276048T3 (en) | 2002-03-05 | 2007-06-16 | Eli Lilly And Company | PURINE DERIVATIVES AS CINASE INHIBITORS. |
MXPA04008671A (en) | 2002-03-08 | 2004-12-06 | Lilly Co Eli | Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors. |
ATE387444T1 (en) * | 2002-05-08 | 2008-03-15 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRROLINES AS KINASE INHIBITORS |
TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
US20090155266A1 (en) * | 2004-01-16 | 2009-06-18 | Yale University | Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases |
EP1804818A4 (en) * | 2004-09-17 | 2009-07-22 | Ford Henry Health System | Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
CN101484575B (en) | 2005-06-08 | 2013-10-02 | 森托科尔公司 | Cellular therapy for ocular degeneration |
WO2007041195A2 (en) * | 2005-09-29 | 2007-04-12 | Janssen Pharmaceutica N.V. | Macroheterocylic compounds as kinase inhibitors |
US7759331B2 (en) * | 2006-03-10 | 2010-07-20 | Janssen Pharmaceutica Nv | Pyridine-containing macroheterococylic compounds as kinase inhibitors |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
AU2007336338A1 (en) | 2006-12-19 | 2008-06-26 | Novartis Ag | Indolylmaleimide derivatives as kinase inhibitors |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
CN101952415B (en) | 2007-07-31 | 2017-06-27 | 生命扫描有限公司 | The differentiation of human embryo stem cell |
CN107574142B (en) | 2007-11-27 | 2021-07-06 | 生命扫描有限公司 | Differentiation of human embryonic stem cells |
CA2710644C (en) | 2007-12-24 | 2016-03-29 | Tibotec Pharmaceuticals | Macrocyclic indoles as hepatitis c virus inhibitors |
WO2009105570A2 (en) | 2008-02-21 | 2009-08-27 | Centocor Ortho Biotech Inc. | Methods, surface modified plates and compositions for cell attachment, cultivation and detachment |
US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
JP5734183B2 (en) | 2008-06-30 | 2015-06-17 | ヤンセン バイオテツク,インコーポレーテツド | Differentiation of pluripotent stem cells |
AU2009281138B2 (en) * | 2008-08-14 | 2014-03-27 | Tibotec Pharmaceuticals | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors |
CA2742267C (en) | 2008-10-31 | 2019-06-04 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
BRPI0919885A2 (en) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine lineage |
RU2555538C2 (en) | 2008-11-20 | 2015-07-10 | Сентокор Орто Байотек Инк. | Culture of pluripotent stem cells on microcarriers |
AU2009316583B2 (en) | 2008-11-20 | 2016-04-21 | Janssen Biotech, Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
RU2540021C2 (en) | 2009-07-20 | 2015-01-27 | Янссен Байотек, Инк. | Differentiating human embryonic stem cells |
GB2485113B (en) | 2009-07-20 | 2016-12-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into cells of the pancreatic endoderm lineage |
EP2456862A4 (en) | 2009-07-20 | 2013-02-27 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
EP2482837A4 (en) | 2009-09-29 | 2013-05-22 | Joslin Diabetes Center Inc | Use of protein kinase c delta (pkcd) inhibitors to treat diabetes, obesity, and hepatic steatosis |
RU2586506C2 (en) | 2009-12-23 | 2016-06-10 | Янссен Байотек, Инк. | Differentiation of human embryonic stem cells |
CN102741395B (en) | 2009-12-23 | 2016-03-16 | 詹森生物科技公司 | The differentiation of human embryo stem cell |
CN104698749B (en) * | 2010-01-25 | 2019-11-19 | 罗门哈斯电子材料有限公司 | Photoresist comprising nitrogenous compound |
ES2538208T3 (en) * | 2010-02-22 | 2015-06-18 | Blanchette Rockefeller Neurosciences Institute | Specific alterations of Alzheimer's disease of protein kinase C epsilon levels (PKC-epsilon) |
AU2011223900A1 (en) | 2010-03-01 | 2012-09-13 | Janssen Biotech, Inc. | Methods for purifying cells derived from pluripotent stem cells |
MX351515B (en) | 2010-05-12 | 2017-10-17 | Janssen Biotech Inc | Differentiation of human embryonic stem cells. |
CA2809305C (en) | 2010-08-31 | 2019-06-11 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
US9528090B2 (en) | 2010-08-31 | 2016-12-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
AU2011296381B2 (en) | 2010-08-31 | 2016-03-31 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
JP2014531425A (en) | 2011-09-02 | 2014-11-27 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | CaMKII, IP3R, calcineurin, p38, and MK2 / 3 inhibitors for treating metabolic disorders of obesity |
AU2012355698B2 (en) | 2011-12-22 | 2018-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
KR20140131999A (en) | 2012-03-07 | 2014-11-14 | 얀센 바이오테크 인코포레이티드 | Defined Media for Expansion and Maintenance of Pluripotent Stem Cells |
CN108103006A (en) | 2012-06-08 | 2018-06-01 | 詹森生物科技公司 | Differentiation of the human embryo stem cell to pancreatic endocrine cell |
KR102036780B1 (en) | 2012-12-31 | 2019-10-25 | 얀센 바이오테크 인코포레이티드 | Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
JP6529440B2 (en) | 2012-12-31 | 2019-06-12 | ヤンセン バイオテツク,インコーポレーテツド | Suspension and clustering of human pluripotent cells for differentiation to pancreatic endocrine cells |
KR102084561B1 (en) | 2012-12-31 | 2020-03-04 | 얀센 바이오테크 인코포레이티드 | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
CA2949056A1 (en) | 2014-05-16 | 2015-11-19 | Janssen Biotech, Inc. | Use of small molecules to enhance mafa expression in pancreatic endocrine cells |
CN107735399B (en) | 2015-07-02 | 2021-01-26 | 特普医药公司 | Chiral diaryl macrocycles as modulators of protein kinases |
BR112018001065A2 (en) * | 2015-07-21 | 2018-09-11 | Tp Therapeutics, Inc. | chiral diaryl macrocycles and uses thereof |
RU2630958C2 (en) * | 2015-12-29 | 2017-09-15 | федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" (МФТИ) | New macrocyclic compounds containing natural 3,7-diazabicycle[3,3,1]nonanonic nucleus and method for their obtaining |
MA45479A (en) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE |
TWI808958B (en) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
WO2018183703A1 (en) | 2017-03-31 | 2018-10-04 | NeuroDiagnostics LLC | Lymphocyte-based morphometric test for alzheimer's disease |
WO2018231743A1 (en) * | 2017-06-12 | 2018-12-20 | Temple University-Of The Commonwealth System Of Higher Education | Protein kinase c-delta targeted therapy for treating radiation injury |
KR102645316B1 (en) | 2017-07-28 | 2024-03-07 | 터닝 포인트 테라퓨틱스, 인크. | Macrocyclic compounds and their uses |
JOP20200152A1 (en) | 2017-12-19 | 2022-10-30 | Turning Point Therapeutics Inc | Macrocyclic compounds for treating disease |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007895A1 (en) * | 1992-09-25 | 1994-04-14 | Schering Corporation | Diindolo compounds and pharmaceutical compositions containing them |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
CN1050844C (en) * | 1993-12-07 | 2000-03-29 | 伊莱利利公司 | Protein kinase C inhibitors |
JP3235840B2 (en) * | 1996-05-01 | 2001-12-04 | イーライ・リリー・アンド・カンパニー | Halo substitution inhibitors of protein kinase C |
WO1999033836A1 (en) * | 1997-12-31 | 1999-07-08 | Cephalon, Inc. | 3'-epimeric k-252a derivatives |
GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
-
2001
- 2001-12-06 AT AT01996227T patent/ATE301661T1/en not_active IP Right Cessation
- 2001-12-06 US US10/008,982 patent/US6828327B2/en not_active Expired - Lifetime
- 2001-12-06 AU AU2737102A patent/AU2737102A/en active Pending
- 2001-12-06 DE DE60112611T patent/DE60112611T2/en not_active Expired - Lifetime
- 2001-12-06 JP JP2002547934A patent/JP2004526676A/en active Pending
- 2001-12-06 EP EP01996227A patent/EP1345946B1/en not_active Expired - Lifetime
- 2001-12-06 MX MXPA03005139A patent/MXPA03005139A/en active IP Right Grant
- 2001-12-06 ES ES01996227T patent/ES2245994T3/en not_active Expired - Lifetime
- 2001-12-06 RU RU2003120442/04A patent/RU2275373C2/en not_active IP Right Cessation
- 2001-12-06 WO PCT/US2001/047866 patent/WO2002046197A1/en active IP Right Grant
- 2001-12-06 CA CA002431187A patent/CA2431187A1/en not_active Abandoned
- 2001-12-06 AU AU2002227371A patent/AU2002227371B2/en not_active Ceased
-
2003
- 2003-11-12 HK HK03108227A patent/HK1055956A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2003120442A (en) | MACROHETEROCYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | |
AU2016365366B2 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
RU2004135382A (en) | SUBSTITUTED PYRROLINS AS KINASE INHIBITORS | |
AU2012339499B2 (en) | Aminoquinazoline derivatives and their salts and methods of use | |
AU2020274083A1 (en) | FGFR inhibitors and methods of use thereof | |
JP2017031207A (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
WO2022174031A1 (en) | Cdk inhibitors and methods of use thereof | |
JP2005531609A5 (en) | ||
AU2009206775A1 (en) | Protein kinase inhibitors and use thereof | |
RU2005123394A (en) | DIAMINE DERIVATIVES | |
JP2009511484A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
WO2020021024A1 (en) | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) | |
MX2012005463A (en) | N-9-substituted purine compounds, compositions and methods of use. | |
EP3936504A1 (en) | Pyrazolo[1,5-a]pyridine derivatives, preparation method therefor and use thereof | |
EP2499143A1 (en) | N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use | |
JP2020521772A (en) | Compounds used as autophagy modulators, and methods for their preparation and use | |
KR102566237B1 (en) | Cycloolefin substituted heteroaromatic compounds and their uses | |
WO2017197151A1 (en) | Phosphotidylinositol 3-kinase inhibitors | |
CN112236416A (en) | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | |
AU2006206555A1 (en) | Novel quinolinium salts and derivatives | |
KR20230167347A (en) | Tricyclic compounds and their uses | |
CA2484702A1 (en) | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
JP2022526147A (en) | CD73 inhibitor, its manufacturing method and application | |
KR20240015688A (en) | Pyrimidine or pyridine derivative and its preparation method and pharmaceutical application | |
KR20180120701A (en) | Tetrahydroisoquinoline derivative |